Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer : A case-control study

Simple item page
dc.contributor.authorMacuks, Ronalds
dc.contributor.authorBaidekalna, Ieva
dc.contributor.authorDoniņa, Simona
dc.contributor.institutionInstitute of Microbiology and Virology
dc.date.accessioned2021-06-10T08:50:01Z
dc.date.available2021-06-10T08:50:01Z
dc.date.issued2012
dc.description.abstractObjective: To analyze differential diagnostic accuracy of urinary human epidydimis secretory protein 4 (HE4)in patients with ovarian tumors. Materials and methods: In the case-control study 23 patients with ovarian cancer, 37 patients with benign ovarian tumors and 18 women in the control group were included. Serum CA125 values and urinary concentrations of HE4were assessed quantitatively. Urinary creatinine concentrations and glomerular filtration rate were also determined and used to calculate ratios to HE4. Results: Higher urinary HE4 concentrations were observed in patients with late stage ovarian cancer (p=0.001) and also in patients with early stage ovarian cancer when compared to patients with benign ovarian tumors (p=0.044). On analysis where all ovarian cancer patients were included, higher diagnostic accuracy was observed with calculated ratio of HE4 to glomerular filtration rate (GFR) to unchanged urinary HE4 concentrations -AUC 0.861 vs. 0.858. When discriminatory accuracy was calculated for urinary HE4/GFR ratio and unchanged urinary HE4 concentrations, the last demonstrated a higher area under the curve - 0.701 vs. 0.602. The urinary HE4/creatinine ratio had lower discriminatory characteristics than unchanged concentrations of urinary HE4. However, HE4 serum concentration was more accurate for discrimination of patients with benign and malignant ovarian tumors when compared to urinary HE4 and CA125 in sera (AUCs were 0.868 for serum HE4 and 0.856 and 0.653 for urinary HE4 and CA125, respectively). Conclusions: Ovarian cancer patients have higher urinary concentrations of human epidydimis secretory protein 4 than patients with benign ovarian tumors. Urinary HE4 has comparable discriminatory accuracy with serum HE4 for benign and malignant ovarian tumors and can be recommended as a non-invasive ovarian cancer riskassessment method.en
dc.description.statusPeer reviewed
dc.format.extent4
dc.format.extent602027
dc.identifier.citationMacuks, R, Baidekalna, I & Doniņa, S 2012, 'Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer : A case-control study', Asian Pacific Journal of Cancer Prevention, vol. 13, no. 9, pp. 4695-4698. https://doi.org/10.7314/APJCP.2012.13.9.4695
dc.identifier.doi10.7314/APJCP.2012.13.9.4695
dc.identifier.issn1513-7368
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/4882
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84874004400&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiagnostic marker
dc.subjectHE4
dc.subjectOvarian cancer
dc.subjectUrine
dc.subject1.6 Biological sciences
dc.subject3.2 Clinical medicine
dc.subject3.3 Health sciences
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectEpidemiology
dc.subjectOncology
dc.subjectPublic Health, Environmental and Occupational Health
dc.subjectCancer Research
dc.subjectSDG 3 - Good Health and Well-being
dc.titleUrinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer : A case-control studyen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Urinary_concentrations_of_human_epidydimis_secretory_protein.pdf
Size:
587.92 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure